Recombinant
RabMAb

Recombinant Anti-Mad2L2/REV7 antibody [EPR13657] (ab180579)

Publishing research using ab180579? Please let us know so that we can cite the reference in this datasheet.

ab180579 has been referenced in 3 publications.

  • Mirman Z  et al. 53BP1-RIF1-shieldin counteracts DSB resection through CST- and Pola-dependent fill-in. Nature 560:112-116 (2018). PubMed: 30022158
  • Nascimento AV  et al. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater 47:71-80 (2017). PubMed: 27697601
  • Tang H  et al. MAD2B-mediated SnoN downregulation is implicated in fibroblast activation and tubulointerstitial fibrosis. Am J Physiol Renal Physiol 311:F207-16 (2016). PubMed: 27122545

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
For licensing inquiries, please contact partnerships@abcam.com

Sign up